Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found no significant difference in the effectiveness of betamethasone dipropionate cream compared to placebo for treating alopecia areata in children, and atopic status did not influence treatment response.

This study concluded that platelet-rich plasma is effective and safe for increasing hair density in androgenetic alopecia, showing significant improvement compared to placebo at 3 and 6 months.

This article details the treatment of a 56-year-old woman with female pattern hair loss using finasteride and minoxidil but reports no new findings.

This study found that a single session of nanofat combined with platelet-rich plasma significantly increased hair density and thickness in male androgenic alopecia patients compared to platelet-rich plasma alone, with effects partially persisting at 12 months.

This study found that hypoxia-conditioned mesenchymal stem cell exosomes increased GM-CSF and decreased IL-1 expression in a dose-dependent manner in a murine model, suggesting potential for treating androgenetic alopecia.

In this study, no significant difference was found between the efficacy of betamethasone dipropionate cream and placebo in treating alopecia areata in children, regardless of atopic status.

This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.

In this study, PRP injections were found to improve hair density and quality in patients with androgenetic alopecia, with a significant reduction in hair loss and high patient satisfaction after three treatment sessions over several months.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This study found that vitamin D deficiency was significantly more prevalent among men with androgenetic alopecia in eastern Uttar Pradesh, India, than in age-matched controls, suggesting a potential link between vitamin D levels and the condition's pathogenesis.

These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.

This review found that platelet-rich plasma therapy improved hair growth and thickness in most studies on alopecia, with the highest improvement seen when combined with Minoxidil.

In this study, early-onset androgenetic alopecia in men was associated with a higher prevalence of metabolic syndrome and carotid atherosclerosis compared to controls, suggesting cardiovascular screening might be beneficial for this group.

This abstract contains no research findings but is a snippet of a website interface for JAMA Dermatology.

This study concludes that phospholipid–polymer hybrid nanoparticles may be an effective delivery system for quercetin in treating androgenic alopecia by improving hair regrowth and preventing hair follicle cell apoptosis in rat models.

This study investigated a liposomal hydrogel system for delivering minoxidil and tretinoin to treat androgenic alopecia, finding that the system enhanced skin permeation of minoxidil while retaining tretinoin on the skin and was non-irritating in animal tests, suggesting its potential effectiveness.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

Finasteride helps improve hair growth in men with hair loss but may increase the risk of erectile dysfunction.

This study found that a cosmetic foam reduced the telogen rate in men with androgenetic alopecia, suggesting a potential benefit against male pattern hair loss.

This study found a significant association between lower vitamin D levels and increased severity of androgenetic alopecia in men.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

This review discusses platelet-rich plasma treatment for androgenetic alopecia, addressing its effectiveness, challenges, and future directions, but reports no new clinical results.

This study found that early-onset male androgenetic alopecia was associated with a higher prevalence of metabolic syndrome compared to age-matched controls.

This study, conducted among Egyptians, found a borderline significant association between the Stul polymorphism of the androgen receptor gene and androgenetic alopecia in males, with higher androgen receptor expression in balding scalp areas.

Cyclosporin doesn't stop hair loss.

This study found that while some patients with severe alopecia areata responded to high-dose prednisolone, the response was inconsistent and the therapy's risks prevent recommending it for general use.

This review discusses the psychological impact of alopecia on women and reports no new clinical findings, highlighting the effect on self-esteem and quality of life.

This review discusses traction alopecia in individuals with Afro-textured hair and emphasizes the importance of education to prevent this condition, but it reports no new clinical results.

In this study, topical application of Hominis Placenta significantly promoted hair regrowth and increased hair density in C57BL/6 mice, suggesting its potential as a treatment for alopecia.